10X Genomics is a biotechnology company that specializes in genomic analysis, providing tools and technologies for researchers in the life sciences sector. The company develops innovative products that enable high-resolution analysis of biological systems, allowing scientists to explore complex interactions at the single-cell level. By offering advanced sequencing and gene expression solutions, 10X Genomics supports a wide range of applications in genomics, transcriptomics, and immunology, aiming to accelerate the discovery of new insights into health and disease. Read More
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u...
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
10x Genomics’ second quarter results came in above Wall Street’s expectations for both revenue and profitability, yet the market responded negatively. Manage...
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...
10x Genomics (NASDAQ:TXG) reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara. Excluding non-recurring settlement revenue in both periods, revenue was $149.4 million, up 3% from a year earlier.
Chief Executive Off
Biotech company 10x Genomics (NASDAQ:TXG) reported Q2 CY2026 results exceeding the market’s revenue expectations, but sales fell by 12.6% year on year to $15...
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Biotech company 10x Genomics (NASDAQ:TXG) reported Q2 CY2026 results topping the market’s revenue expectations, but sales fell by 12.6% year on year to $151 ...
Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results this Thursday after market close. Here’s what to expect. 10x Genomics beat anal...
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HC...
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...
Check out the companies making headlines this week: Qualcomm (NASDAQ:QCOM): Wireless chipmaker Qualcomm (NASDAQ:QCOM) fell by 4.7% on Wednesday after a lever...
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 6.8% in the morning session after Barclays boosted its price target to $40 per shar...
The past six months have been a windfall for 10x Genomics’s shareholders. The company’s stock price has jumped 116%, setting a new 52-week high of $34.69 per...
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
10x Genomics' first quarter results were met with a negative market reaction, despite exceeding Wall Street’s revenue and earnings expectations. Management c...
